Plaque Psoriasis and Weight Management
This study aims to see how well adding a new treatment can help people with moderate-to-severe plaque psoriasis and obesity or overweight who also have at least one weight-related health issue. The study will last up to 12 months.
Study site: NeoClinical Research
- Psoriasis
- Overweight and obesity
- About the Study
- We’re looking into how well a new treatment can work alongside existing therapy for people dealing with moderate-to-severe plaque psoriasis and obesity or overweight, particularly those with at least one weight-related health issue. The study will last up to 12 months.
- What does the study involve?
- The treatment will be given as an injection under the skin.
What to expect
- Placebo
- Everyone receives an active treatment.
- Who can participate?
- We're looking for adults who: * Have moderate-to-severe plaque psoriasis diagnosed by a healthcare professional. * Have a body mass index (BMI) of 30 or higher (obesity) or 27 to less than 30 (overweight) with at least one weight-related health issue like high blood pressure or type 2 diabetes. * Have been on ixekizumab treatment for about 3 months before starting this study. Think you might qualify? Apply to find out!
Where is the study taking place?
Palmetto Medical Plaza
Study details
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 4: studying a treatment that is already approved
- Dates
- March 2025 to May 2028 (expected)
- Size
- 200 participants across all sites
- Healthy volunteers
- Only people with the condition
Study details are from ClinicalTrials.gov. The rest of this page is written by the study site for patients and may summarize or reword the registry record, which is the official text. A study listed on ClinicalTrials.gov has not necessarily been reviewed or approved by the U.S. government.
About NeoClinical Research
NeoClinical Research is a leading, multi-therapeutic clinical research center based in South Florida that bridges the gap between leading pharmaceutical companies and diverse patient populations.